Great West Life Assurance Co. Can raised its position in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 65.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,160 shares of the company’s stock after purchasing an additional 1,639 shares during the quarter. Great West Life Assurance Co. Can’s holdings in Aerie Pharmaceuticals were worth $204,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. California Public Employees Retirement System purchased a new stake in shares of Aerie Pharmaceuticals during the first quarter worth $231,000. Aperio Group LLC increased its position in shares of Aerie Pharmaceuticals by 4.7% during the second quarter. Aperio Group LLC now owns 4,914 shares of the company’s stock worth $258,000 after acquiring an additional 219 shares during the period. Sei Investments Co. increased its position in shares of Aerie Pharmaceuticals by 53,632.1% during the second quarter. Sei Investments Co. now owns 15,045 shares of the company’s stock worth $790,000 after acquiring an additional 15,017 shares during the period. Schwab Charles Investment Management Inc. increased its position in shares of Aerie Pharmaceuticals by 1.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 138,289 shares of the company’s stock worth $7,268,000 after acquiring an additional 2,183 shares during the period. Finally, Rhumbline Advisers increased its position in shares of Aerie Pharmaceuticals by 3.7% during the second quarter. Rhumbline Advisers now owns 34,913 shares of the company’s stock worth $1,835,000 after acquiring an additional 1,237 shares during the period.

Aerie Pharmaceuticals Inc (NASDAQ AERI) opened at $60.50 on Wednesday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 15.24 and a current ratio of 15.24. The company has a market cap of $2,220.00, a price-to-earnings ratio of -18.06 and a beta of 1.11. Aerie Pharmaceuticals Inc has a 12 month low of $37.02 and a 12 month high of $66.60.

A number of analysts have recently weighed in on AERI shares. Mizuho started coverage on Aerie Pharmaceuticals in a research report on Wednesday, September 6th. They set a “buy” rating and a $70.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $65.00 price objective on shares of Aerie Pharmaceuticals in a research report on Sunday, September 17th. Canaccord Genuity reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Friday, September 22nd. Cowen reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Thursday, October 5th. Finally, Zacks Investment Research lowered Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the company. Aerie Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $72.00.

COPYRIGHT VIOLATION WARNING: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/12/27/aerie-pharmaceuticals-inc-aeri-shares-bought-by-great-west-life-assurance-co-can.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.